Top stories from TTO's July newsletter:
Advanced Conductor Technologies to Develop CU High-Performance Superconducting Cable
Ten CU Research Groups Receive Tech Commercialization Grants from State of Colorado
GlobeImmune Files for IPO of Up to $69 Million
CU licensee GlobeImmune Inc. filed plans for an initial public offering of up to $69M as the biopharmaceutical company looks to raise funds to advance its infectious disease product candidates.
Sobi Files Kineret Application with FDA for NOMID Indication
The US Federal Drug Administration (FDA) has received an application from Sobi (Swedish Orphan Biovitrum, previously known as Biovitrum) for Kineret® (anakinra) for the indication of neonatal-onset multisystem inflammatory disease (NOMID). Kineret was developed at CU, and is marketed internationally by Sobi following a license agreement with Amgen.
Read the full newsletter, or sign up to receive a monthly email update.
7 hours ago